Demand for Cannabis Concentrates are the Fastest Growing of all Related Product Categories
Vancouver, British Columbia–(Newsfile Corp. – July 21, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce a Memorandum of Understanding with award-winning and leading legacy cannabis brand, the Summit Boys, to co-brand a series of high-quality cannabis concentrates.
The Summit Boys are a well-known legacy recreational cannabis product producers (operating since 2016 under prop 215 and with a cult-like following on Instagram of over 66,000 followers). In this agreement, Lyfted Farms (a TransCanna subsidiary), will supply high-quality cannabis flower to the Summit Boys for processing into a line of popular cannabis concentrates branded as ‘Caviar.’
In 2019, the Summit Boys earned 14 awards in the Bay Area Cannabis Cup in several categories, including for Best Product and Hybrid Concentrate for this same Caviar product. The line of ‘White Caviar’ branded products are what The Summit Boys are best known for.
Cannabis concentrates have a greater proportion of cannabinoids and terpenes when compared to natural cannabis flowers, and can increase the potency of cannabis flower. Demand for these concentrates are also the fastest-growing of any cannabis product in the California market (the largest Cannabis market globally).
“This co-branding of the already famous Caviar product now powered by Lyfted’s flower is great news for cannabis consumers,” says Bob Blink, TransCanna CEO. “For us, it’s another example of our strategy to align with high-quality producers and already successful players in the industry-this time with the added value of the Summit Boys’ grassroots following. But for the more sophisticated California cannabis market, this partnership will mean an even higher quality product for consumers.”
“As a dedicated brand to California Cannabis market, we wanted to find like-minded partners. Since meeting the Lyfted team, they have earned our respect, and we definitely look forward to working together. There are many things that excite us, but being able to co-brand and scale now that the Daly Facility is licensed is a huge opportunity, ” stated Mike Larson, Summit Boys CEO.
News of this agreement follows an announcement by TransCanna that the Company was awarded its final operating license for the 196,000 square foot Daly Facility by the California Bureau of Cannabis Control July 10, 2020.
About TransCanna Holdings Inc.
TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.
On behalf of the Board of Directors,
Bob Blink, CEO
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.
The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.
These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60171
PURA Plows Forward With Farmersville Brands And Stock Dividend
Dallas, Texas–(Newsfile Corp. – September 30, 2020) – Puration, Inc. (OTC Pink: PURA) management today communicated assurance that the company’s Farmersville Brands strategy to include the acquisition of 72-acre property in Farmersville, Texas and infused with a $100 million planned investment is moving forward. Management also confirms intentions to promptly execute on the distribution of a previously announced stock dividend. With both coming at the end of the third quarter, management decided to close the quarter before the definitive execution of the property acquisition and the dividend. PURA expects to make prompt definitive moves on both next week. Management is also pleased to highlight the impending initiation of a third production run this year of its EVERx CBD Sports Water in conjunction with ongoing consistent sales in the face of this year’s pandemic challenges.
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64943
The Top Reasons Lithium Prices Will Soon Spike Higher Again
Houston, Texas–(Newsfile Corp. – September 30, 2020) – The world could run into a massive lithium supply crunch.
Thanks in part to the electric vehicle boom that doesn’t look to cool off any time soon.
In fact, “A global push for EV adoption, helped by government subsidies and incentives, means that demand for lithium is not going away. Companies like Volkswagen, Ford, Mercedes and Amazon having started shifting their focus to electric vehicles,” reports Bloomberg.
According to the Boston Consulting Group, by 2025, EVs could account for a third of all auto sales. By 2030, EVs could surpass combustion engine vehicles with a market share of 51%.
Helping to fuel the boom, Tesla just signed a lithium ore supply deal with Piedmont Lithium.
“The initial five-year agreement implies that Piedmont will supply about a third of its planned 160,000-tonnes-per-year spodumene concentrate produce from its deposits in North Carolina. Both companies have an option to extend the deal for another five years,” added Reuters.
With demand increasing, it’s only a matter of time before lithium prices spike again.
E3 Metals Corp. (TSXV: ETMC) (OTC Pink: EEMMF) Could Be a Big Part of the Lithium Boom
E3 Metals Corp. just hosted the Energy Minister, Sonya Savage, from the Government of Alberta at the Company’s offices in Calgary.
During this visit, the government announced it has assembled a five-member panel of experts from the metals and mining industry whose strategic advice will help government unlock the province’s vast mineral potential, including lithium. The panel will support the province in its efforts to diversify its economy and become a world leader in mineral resource production.
“We are very happy to host the Minister of Energy at our offices today. This announcement solidifies the province’s commitment for the development of critical minerals. E3 Metals is on the forefront of lithium development in Alberta, a critical mineral that can be produced on the backbone of the oil industry. Alberta has a skilled energy labour force already in place that is well positioned to support an emerging minerals sector,” said Chris Doornbos, President and Chief Executive Officer of E3 Metals.
“As E3 Metals works to commercialize lithium production in Alberta, we are excited to participate in this broader effort to position Alberta as an international player in a world increasingly focused on battery materials,” he added.
In addition, according to Sonya Savage, Minister of Energy, Government of Alberta, “We (the Alberta government) need to take bold action to diversify our economy by exploring… minerals. Our government’s efforts will support the development… of the mineral sector including the ground breaking work that is being done by Alberta companies such as E3 (Metals). Our ultimate goal (is to become) a global destination for mineral investment exploration and development.”
The announcement by the province complements the Canada-U.S. Joint Action Plan on Critical Minerals Collaboration, which focuses on securing and developing critical mineral supply chains. Lithium, graphite, cobalt and rare earth elements, all of which play an important role in the production of lithium-ion batteries and the energy storage sector, are listed as critical minerals. To date, many other developed economies have put in place a critical minerals strategy including the European Union, Japan, Korea and Australia.
For more information, visit the company’s website at https://www.e3metalscorp.com
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and E3 Metals Corp. Winning Media has been paid two thousand dollars for advertising and marketing services for E3 Metals Corp. We own ZERO shares of E3 Metals Corp. Please click here for full disclaimer.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64942
PAOG Cannabis Pharmaceutical Research Initiative Gains New Traction
Sandusky, Ohio–(Newsfile Corp. – September 30, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today indicated plans to reveal new information on the Company’s initiative to expand its cannabis pharmaceutical treatment research beyond its current focus on Chronic Obstructive Pulmonary Disease (COPD).
In a media interview scheduled for release on Friday, October 2nd, PAOG Jim DiPrima will highlight a new pharmaceutical cannabis research expert resource engaged by the company to bring new industry recognized expertise to move PAOG’s cannabis pharmaceutical asset forward.
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
With RespRx now in house, PAOG has engaged multiple new experts from both the university and commercial medical research community to evaluate the RespRx formula, the formulation process and the test results.
The expert evaluation has reviewed RespRx in conjunction with other publicly available cannabis treatment research. Two studies in particular, both of which highlight the research behind GW Pharmaceuticals’ cannabinoid treatments, shed light on PAOG’s wider opportunity stemming from RespRx, the process to derive RespRx and the clinical trials to date behind RespRx.
One of the two studies is focused on CBD and the other on THC. The research seems to indicate CBD has both an impact on hyper-immune responses that might result in conditions like a cytokine storm which impacts many COVID-19 patients, and positive stimulation of immune responses that fight bad cells. The THC report seems to validate its ability to relieve pain, but it also indicates immune response manipulation capabilities to include anti-inflammatory reactions and the stimulation of immune responses to fight bad cells.
CBD Research – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173676/
THC Research – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219460/
In summary, existing publicly available cannabis treatment research further supports the research findings behind RespRx, and at the same time, the publicly available research sheds light on the expanded potential of PAOG’s RespRx overall technology.
The growing body of cannabis research is building convincing evidence behind how specific cannabinoids can beneficially impact specific immune responses. The research behind RespRx demonstrates how the process to derive RespRx can be manipulated to target specific cannabinoid extractions. Accordingly, as advancing cannabis research unveils further evidence behind how specific cannabinoids beneficially impact specific immune responses, PAOG is optimistic that it can utilize its overall cannabis extraction process to effectively derive formals with high concentrations of target cannabinoids. Hence, PAOG sees a more broad future of developing cannabis treatments beyond COPD.
In conjunction with PAOG’s acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) to develop a proprietary cultivar to support PAOG’s cannabis pharmaceutical treatment objectives.
PAOG has announced plans with PURA to expand upon PAOG’s hemp cultivation business to develop a proprietary hemp cultivar. PAOG and PURA are partnering on PURA’s Farmersville Brands initiative.
PAOG’s Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments.
PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.
PURA recently announced a year long initiative to transition PURA from a CBD sports beverage manufacturer into a hemp conglomerate built on lifestyle brand with a broad CBD consumer products reach, and a leading industrial hemp initiative. The brand name is Farmersville Brands and as part of their strategy, PURA has entered into a letter of intent (LOI) agreement to acquire 72 acers of agricultural property in Farmersville, Texas. PURA’s year long initiative includes plans to see the Farmersville Brand strategy infused with a $100 million investment.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64940
Cannabis4 weeks ago
3 Rivers Biotech to Establish Genetic Fingerprinting and Pathogen Testing Lab
Cannabis3 weeks ago
Rapid Screening Tests Are Still Struggling to Keep up with Demand
Cannabis4 weeks ago
DGDM’s Disruptive Pesticide Product Targeted to MJ Growers Passes Testing Trials During Pre-EPA Certification Period
Cannabis3 weeks ago
DGDM Provides Further Analysis of Specific Trial Testing Results of Its Disruptive Pesticide Product Targeted at MJ Growers
Cannabis2 weeks ago
Sixth Wave Innovations Announces Collaborative “Green” Test Initiatives with Mining and Process Solutions (Australia)
Cannabis4 weeks ago
Fernhill Beverage Branches Out for Success!
Cannabis4 weeks ago
MediPharm Labs Enters Growing Latin American Medical Cannabis Market; Enters Supply Agreement With Cann Farm Peru
Cannabis3 weeks ago
Monument Health Chooses Nuance Dragon Ambient eXperience to Transform Physician-Patient Encounters with Ambient Clinical Intelligence